Literature DB >> 34011939

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.

Ge Song1,2,3, Wan-Ting He1,2,3, Sean Callaghan1,2,3, Fabio Anzanello1,2,3, Deli Huang1, James Ricketts1, Jonathan L Torres4, Nathan Beutler1, Linghang Peng1, Sirena Vargas1,2,3, Jon Cassell1,2,3, Mara Parren1, Linlin Yang1, Caroline Ignacio5, Davey M Smith5, James E Voss1, David Nemazee1, Andrew B Ward2,3,4, Thomas Rogers1,5, Dennis R Burton6,7,8,9, Raiees Andrabi10,11,12.   

Abstract

Pre-existing immunity to seasonal endemic coronaviruses could have profound consequences for antibody responses to SARS-CoV-2, induced from natural infection or vaccination. A first step to establish whether pre-existing responses can impact SARS-CoV-2 infection is to understand the nature and extent of cross-reactivity in humans to coronaviruses. Here we compare serum antibody and memory B cell responses to coronavirus spike proteins from pre-pandemic and SARS-CoV-2 convalescent donors using binding and functional assays. We show weak evidence of pre-existing SARS-CoV-2 cross-reactive serum antibodies in pre-pandemic donors. However, we find evidence of pre-existing cross-reactive memory B cells that are activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, including SARS-CoV-1 and endemic coronaviruses. We identify one cross-reactive neutralizing antibody specific to the S2 subunit of the S protein. Our results suggest that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.

Entities:  

Year:  2021        PMID: 34011939     DOI: 10.1038/s41467-021-23074-3

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  49 in total

Review 1.  Neutralization and antibody-dependent enhancement of dengue viruses.

Authors:  Scott B Halstead
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

2.  Coronavirus Infections-More Than Just the Common Cold.

Authors:  Catharine I Paules; Hilary D Marston; Anthony S Fauci
Journal:  JAMA       Date:  2020-02-25       Impact factor: 56.272

3.  A perspective on potential antibody-dependent enhancement of SARS-CoV-2.

Authors:  Ann M Arvin; Katja Fink; Michael A Schmid; Andrea Cathcart; Roberto Spreafico; Colin Havenar-Daughton; Antonio Lanzavecchia; Davide Corti; Herbert W Virgin
Journal:  Nature       Date:  2020-07-13       Impact factor: 49.962

4.  Defining B cell immunodominance to viruses.

Authors:  Davide Angeletti; James S Gibbs; Matthew Angel; Ivan Kosik; Heather D Hickman; Gregory M Frank; Suman R Das; Adam K Wheatley; Madhu Prabhakaran; David J Leggat; Adrian B McDermott; Jonathan W Yewdell
Journal:  Nat Immunol       Date:  2017-02-13       Impact factor: 25.606

5.  Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43.

Authors:  Xiao-Yan Che; Li-Wen Qiu; Zhi-Yong Liao; Ya-di Wang; Kun Wen; Yu-Xian Pan; Wei Hao; Ya-Bo Mei; Vincent C C Cheng; Kwok-Yung Yuen
Journal:  J Infect Dis       Date:  2005-05-06       Impact factor: 5.226

6.  A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.

Authors:  Angkana T Huang; Bernardo Garcia-Carreras; Matt D T Hitchings; Bingyi Yang; Leah C Katzelnick; Susan M Rattigan; Brooke A Borgert; Carlos A Moreno; Benjamin D Solomon; Luke Trimmer-Smith; Veronique Etienne; Isabel Rodriguez-Barraquer; Justin Lessler; Henrik Salje; Donald S Burke; Amy Wesolowski; Derek A T Cummings
Journal:  Nat Commun       Date:  2020-09-17       Impact factor: 14.919

7.  Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer.

Authors:  Liwei Cao; Matthias Pauthner; Raiees Andrabi; Kimmo Rantalainen; Zachary Berndsen; Jolene K Diedrich; Sergey Menis; Devin Sok; Raiza Bastidas; Sung-Kyu Robin Park; Claire M Delahunty; Lin He; Javier Guenaga; Richard T Wyatt; William R Schief; Andrew B Ward; John R Yates; Dennis R Burton; James C Paulson
Journal:  Nat Commun       Date:  2018-09-12       Impact factor: 14.919

8.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.

Authors:  Alba Grifoni; Daniela Weiskopf; Sydney I Ramirez; Jose Mateus; Jennifer M Dan; Carolyn Rydyznski Moderbacher; Stephen A Rawlings; Aaron Sutherland; Lakshmanane Premkumar; Ramesh S Jadi; Daniel Marrama; Aravinda M de Silva; April Frazier; Aaron F Carlin; Jason A Greenbaum; Bjoern Peters; Florian Krammer; Davey M Smith; Shane Crotty; Alessandro Sette
Journal:  Cell       Date:  2020-05-20       Impact factor: 66.850

9.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.

Authors:  Kevin W Ng; Nikhil Faulkner; Georgina H Cornish; Annachiara Rosa; Ruth Harvey; Saira Hussain; Rachel Ulferts; Christopher Earl; Antoni G Wrobel; Donald J Benton; Chloe Roustan; William Bolland; Rachael Thompson; Ana Agua-Doce; Philip Hobson; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine F Houlihan; Kirsty Thomson; Emilie Sanchez; Gee Yen Shin; Moira J Spyer; Dhira Joshi; Nicola O'Reilly; Philip A Walker; Svend Kjaer; Andrew Riddell; Catherine Moore; Bethany R Jebson; Meredyth Wilkinson; Lucy R Marshall; Elizabeth C Rosser; Anna Radziszewska; Hannah Peckham; Coziana Ciurtin; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve J Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis
Journal:  Science       Date:  2020-11-06       Impact factor: 47.728

10.  Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike.

Authors:  Jérémie Prévost; Romain Gasser; Guillaume Beaudoin-Bussières; Jonathan Richard; Ralf Duerr; Annemarie Laumaea; Sai Priya Anand; Guillaume Goyette; Mehdi Benlarbi; Shilei Ding; Halima Medjahed; Antoine Lewin; Josée Perreault; Tony Tremblay; Gabrielle Gendron-Lepage; Nicolas Gauthier; Marc Carrier; Diane Marcoux; Alain Piché; Myriam Lavoie; Alexandre Benoit; Vilayvong Loungnarath; Gino Brochu; Elie Haddad; Hannah D Stacey; Matthew S Miller; Marc Desforges; Pierre J Talbot; Graham T Gould Maule; Marceline Côté; Christian Therrien; Bouchra Serhir; Renée Bazin; Michel Roger; Andrés Finzi
Journal:  Cell Rep Med       Date:  2020-09-30
View more
  92 in total

Review 1.  Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.

Authors:  Yu-Chyi Hwang; Ruei-Min Lu; Shih-Chieh Su; Pao-Yin Chiang; Shih-Han Ko; Feng-Yi Ke; Kang-Hao Liang; Tzung-Yang Hsieh; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2022-01-04       Impact factor: 8.410

2.  Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.

Authors:  Muriel Aguilar-Bretones; Brenda M Westerhuis; Matthijs P Raadsen; Erwin de Bruin; Felicity D Chandler; Nisreen Ma Okba; Bart L Haagmans; Thomas Langerak; Henrik Endeman; Johannes Pc van den Akker; Diederik Ampj Gommers; Eric Cm van Gorp; Corine H GeurtsvanKessel; Rory D de Vries; Ron Am Fouchier; Barry Hg Rockx; Marion Pg Koopmans; Gijsbert P van Nierop
Journal:  J Clin Invest       Date:  2021-11-01       Impact factor: 14.808

3.  Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.

Authors:  Rachna T Shroff; Pavani Chalasani; Ran Wei; Daniel Pennington; Grace Quirk; Marta V Schoenle; Kameron L Peyton; Jennifer L Uhrlaub; Tyler J Ripperger; Mladen Jergović; Shelby Dalgai; Alexander Wolf; Rebecca Whitmer; Hytham Hammad; Amy Carrier; Aaron J Scott; Janko Nikolich-Žugich; Michael Worobey; Ryan Sprissler; Michael Dake; Bonnie J LaFleur; Deepta Bhattacharya
Journal:  Nat Med       Date:  2021-09-30       Impact factor: 53.440

Review 4.  The humoral response and antibodies against SARS-CoV-2 infection.

Authors:  Hai Qi; Linqi Zhang; Bo Liu; Xinquan Wang
Journal:  Nat Immunol       Date:  2022-06-27       Impact factor: 31.250

5.  Decay of Fc-dependent antibody functions after mild to moderate COVID-19.

Authors:  Wen Shi Lee; Kevin John Selva; Samantha K Davis; Bruce D Wines; Arnold Reynaldi; Robyn Esterbauer; Hannah G Kelly; Ebene R Haycroft; Hyon-Xhi Tan; Jennifer A Juno; Adam K Wheatley; P Mark Hogarth; Deborah Cromer; Miles P Davenport; Amy W Chung; Stephen J Kent
Journal:  Cell Rep Med       Date:  2021-05-09

6.  SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.

Authors:  Fatima Amanat; Mahima Thapa; Tinting Lei; Shaza M Sayed Ahmed; Daniel C Adelsberg; Juan Manuel Carreño; Shirin Strohmeier; Aaron J Schmitz; Sarah Zafar; Julian Q Zhou; Willemijn Rijnink; Hala Alshammary; Nicholas Borcherding; Ana Gonzalez Reiche; Komal Srivastava; Emilia Mia Sordillo; Harm van Bakel; Jackson S Turner; Goran Bajic; Viviana Simon; Ali H Ellebedy; Florian Krammer
Journal:  Cell       Date:  2021-06-08       Impact factor: 66.850

7.  Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.

Authors:  Fred D Mast; Peter C Fridy; Natalia E Ketaren; Junjie Wang; Erica Y Jacobs; Jean Paul Olivier; Tanmoy Sanyal; Kelly R Molloy; Fabian Schmidt; Magdalena Rutkowska; Yiska Weisblum; Lucille M Rich; Elizabeth R Vanderwall; Nicholas Dambrauskas; Vladimir Vigdorovich; Sarah Keegan; Jacob B Jiler; Milana E Stein; Paul Dominic B Olinares; Louis Herlands; Theodora Hatziioannou; D Noah Sather; Jason S Debley; David Fenyö; Andrej Sali; Paul D Bieniasz; John D Aitchison; Brian T Chait; Michael P Rout
Journal:  Elife       Date:  2021-12-07       Impact factor: 8.140

8.  Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice.

Authors:  Huibin Lv; Owen Tak-Yin Tsang; Ray T Y So; Yiquan Wang; Meng Yuan; Hejun Liu; Garrick K Yip; Qi Wen Teo; Yihan Lin; Weiwen Liang; Jinlin Wang; Wilson W Ng; Ian A Wilson; J S Malik Peiris; Nicholas C Wu; Chris K P Mok
Journal:  Eur J Immunol       Date:  2021-06-22       Impact factor: 6.688

9.  A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.

Authors:  Delphine C Malherbe; Drishya Kurup; Christoph Wirblich; Adam J Ronk; Chad Mire; Natalia Kuzmina; Noor Shaik; Sivakumar Periasamy; Matthew A Hyde; Julie M Williams; Pei-Yong Shi; Matthias J Schnell; Alexander Bukreyev
Journal:  NPJ Vaccines       Date:  2021-07-22       Impact factor: 7.344

10.  Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern.

Authors:  Wenwei Li; Yaozong Chen; Jérémie Prévost; Irfan Ullah; Maolin Lu; Shang Yu Gong; Alexandra Tauzin; Romain Gasser; Dani Vézina; Sai Priya Anand; Guillaume Goyette; Debashree Chaterjee; Shilei Ding; William D Tolbert; Michael W Grunst; Yuxia Bo; Shijian Zhang; Jonathan Richard; Fei Zhou; Rick K Huang; Lothar Esser; Allison Zeher; Marceline Côté; Priti Kumar; Joseph Sodroski; Di Xia; Pradeep D Uchil; Marzena Pazgier; Andrés Finzi; Walther Mothes
Journal:  bioRxiv       Date:  2021-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.